Fatima Zohra Delma, Willem J G Melchers, Paul E Verweij, Jochem B Buil
{"title":"欧盟肉汤微量稀释法测定的 5-氟胞嘧啶和念珠菌物种的野生型 MIC 分布和流行病学临界值。","authors":"Fatima Zohra Delma, Willem J G Melchers, Paul E Verweij, Jochem B Buil","doi":"10.1093/jacamr/dlae153","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>EUCAST has established clinical breakpoints and epidemiological cutoff values (ECOFFs) for <i>Candida</i> spp. However, limited data are available for 5-flucytosine (5-FC). We assessed the <i>in vitro</i> susceptibility of 5-FC against a large collection of clinical <i>Candida</i> species using EUCAST methodology and determined the associated ECOFFs.</p><p><strong>Methods: </strong>A total of 5622 <i>Candida</i> isolates were collected from patients across the Netherlands between 2008 and 2024. 5-FC MICs were determined using the EUCAST microbroth dilution reference method. Furthermore, MICs were extracted from the EUCAST website. The MICs from this study and those extracted were used to determine ECOFFs and local ECOFFs (L-ECOFFs).</p><p><strong>Results: </strong>5-FC exhibited potent <i>in vitro</i> activity against <i>C. albicans</i>, <i>N. glabratus</i> and <i>C. parapsilosis,</i> while decreased susceptibility was observed for <i>C. tropicalis, Pichia species, K. marxianus, Y. lipolytica,</i> and <i>C. auris.</i> The ECOFFs (mg/L) and the percentages of WT isolates for 5-FC were: <i>C. albicans</i>: 0.5 (97.2%), <i>N. glabratus</i>: 0.5 (96.6%), <i>C. parapsilosis</i>: 0.5 (99.5%) and <i>P. kudriavzevii</i>: 8 (99.4%). The L-ECOFF (mg/L) and the percentages of WT isolates for 5-FC were: <i>C. dubliniensis</i>: 0.25 (96.8%), <i>C. tropicalis</i>: 0.25 (67.2%), <i>K. marxianus</i>: 0.25 (48.0%), <i>C. lusitaniae</i>: 0.25 (86.5%), <i>M. guillermondii</i>: 0.125 (95.9%) and <i>P. norvegiensis</i>: 8 (94.2%).</p><p><strong>Conclusions: </strong>5-FC remains a valuable drug to manage difficult-to-treat invasive <i>Candida</i> infections. <i>In vitro</i> susceptibility cannot be predicted based on species identification for most <i>Candida</i> species, but requires MIC-testing. ECOFFs will help to interpret the MICs to support treatment decisions.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11450473/pdf/","citationCount":"0","resultStr":"{\"title\":\"Wild-type MIC distributions and epidemiological cutoff values for 5-flucytosine and <i>Candida</i> species as determined by EUCAST broth microdilution.\",\"authors\":\"Fatima Zohra Delma, Willem J G Melchers, Paul E Verweij, Jochem B Buil\",\"doi\":\"10.1093/jacamr/dlae153\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>EUCAST has established clinical breakpoints and epidemiological cutoff values (ECOFFs) for <i>Candida</i> spp. However, limited data are available for 5-flucytosine (5-FC). We assessed the <i>in vitro</i> susceptibility of 5-FC against a large collection of clinical <i>Candida</i> species using EUCAST methodology and determined the associated ECOFFs.</p><p><strong>Methods: </strong>A total of 5622 <i>Candida</i> isolates were collected from patients across the Netherlands between 2008 and 2024. 5-FC MICs were determined using the EUCAST microbroth dilution reference method. Furthermore, MICs were extracted from the EUCAST website. The MICs from this study and those extracted were used to determine ECOFFs and local ECOFFs (L-ECOFFs).</p><p><strong>Results: </strong>5-FC exhibited potent <i>in vitro</i> activity against <i>C. albicans</i>, <i>N. glabratus</i> and <i>C. parapsilosis,</i> while decreased susceptibility was observed for <i>C. tropicalis, Pichia species, K. marxianus, Y. lipolytica,</i> and <i>C. auris.</i> The ECOFFs (mg/L) and the percentages of WT isolates for 5-FC were: <i>C. albicans</i>: 0.5 (97.2%), <i>N. glabratus</i>: 0.5 (96.6%), <i>C. parapsilosis</i>: 0.5 (99.5%) and <i>P. kudriavzevii</i>: 8 (99.4%). The L-ECOFF (mg/L) and the percentages of WT isolates for 5-FC were: <i>C. dubliniensis</i>: 0.25 (96.8%), <i>C. tropicalis</i>: 0.25 (67.2%), <i>K. marxianus</i>: 0.25 (48.0%), <i>C. lusitaniae</i>: 0.25 (86.5%), <i>M. guillermondii</i>: 0.125 (95.9%) and <i>P. norvegiensis</i>: 8 (94.2%).</p><p><strong>Conclusions: </strong>5-FC remains a valuable drug to manage difficult-to-treat invasive <i>Candida</i> infections. <i>In vitro</i> susceptibility cannot be predicted based on species identification for most <i>Candida</i> species, but requires MIC-testing. ECOFFs will help to interpret the MICs to support treatment decisions.</p>\",\"PeriodicalId\":14594,\"journal\":{\"name\":\"JAC-Antimicrobial Resistance\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-10-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11450473/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAC-Antimicrobial Resistance\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/jacamr/dlae153\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAC-Antimicrobial Resistance","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jacamr/dlae153","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Wild-type MIC distributions and epidemiological cutoff values for 5-flucytosine and Candida species as determined by EUCAST broth microdilution.
Objectives: EUCAST has established clinical breakpoints and epidemiological cutoff values (ECOFFs) for Candida spp. However, limited data are available for 5-flucytosine (5-FC). We assessed the in vitro susceptibility of 5-FC against a large collection of clinical Candida species using EUCAST methodology and determined the associated ECOFFs.
Methods: A total of 5622 Candida isolates were collected from patients across the Netherlands between 2008 and 2024. 5-FC MICs were determined using the EUCAST microbroth dilution reference method. Furthermore, MICs were extracted from the EUCAST website. The MICs from this study and those extracted were used to determine ECOFFs and local ECOFFs (L-ECOFFs).
Results: 5-FC exhibited potent in vitro activity against C. albicans, N. glabratus and C. parapsilosis, while decreased susceptibility was observed for C. tropicalis, Pichia species, K. marxianus, Y. lipolytica, and C. auris. The ECOFFs (mg/L) and the percentages of WT isolates for 5-FC were: C. albicans: 0.5 (97.2%), N. glabratus: 0.5 (96.6%), C. parapsilosis: 0.5 (99.5%) and P. kudriavzevii: 8 (99.4%). The L-ECOFF (mg/L) and the percentages of WT isolates for 5-FC were: C. dubliniensis: 0.25 (96.8%), C. tropicalis: 0.25 (67.2%), K. marxianus: 0.25 (48.0%), C. lusitaniae: 0.25 (86.5%), M. guillermondii: 0.125 (95.9%) and P. norvegiensis: 8 (94.2%).
Conclusions: 5-FC remains a valuable drug to manage difficult-to-treat invasive Candida infections. In vitro susceptibility cannot be predicted based on species identification for most Candida species, but requires MIC-testing. ECOFFs will help to interpret the MICs to support treatment decisions.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
